With policymakers and industry stakeholders increasingly focused on the cost savings opportunities tied to biosimilars, a Health Affairs study sheds light on some of the factors that influence uptake of these near-copies of pricey biologic medications.
Among almost 200,000 commercial and Medicare Advantage enrollees who newly initiated one of seven biologic drugs with available biosimilar versions...